Department of HBP SURGERY II, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, Guangdong, 510180, China.
Department of Obstetrics, the First People's Hospital of Foshan, Foshan, Guangdong, 528000, China.
Eur J Surg Oncol. 2021 Mar;47(3 Pt B):690-698. doi: 10.1016/j.ejso.2020.11.121. Epub 2020 Nov 17.
Hepatic angiosarcoma(HAS) is rare and is the primary vascular-derived malignancy of the liver. Its clinical characteristics, therapeutic strategy management, and the outcome are unclear.
This is a retrospective study of patients from the SEER database. Survival analysis was performed by the Kaplan-Meier method. Univariate and multivariate Cox models were used to identify risk factors. Propensity Score Matching(PSM) analysis was used to remove confounding bias. The nomogram was constructed, and the performance was measured using the C-index.
A total of 300 HAS patients diagnosed between 1975 and 2016 were identified for this study, with an estimated median cancer-specific survival(CSS) of 1 month. The median CSS was 6 months in both the surgery and chemotherapy groups. Age(HR = 1.5206, p = 0.0058), sex(HR = 1.3906, p = 0.0391), SEER stage(HR = 1.4426, p < 0.0001), surgery(HR = 0.4493, p = 0.0001) and chemotherapy(HR = 0.28161, p < 0.0001) are potential independent prognostic factors. Of these HAS patients, 29 received surgical treatment without chemotherapy, and 63 received chemotherapy without surgery. A 1:1 PSM was performed to select candidates from the surgery-only group and the chemotherapy-only group. The survival analysis showed that the median survival time was 3 months in the surgery-only cohort and 5 months in the chemotherapy-only cohort, and there was no statistical difference between the two groups. Finally, a nomogram was constructed, with a C-index of 0.754.
HAS is uncommon and has a poor prognosis. It was found that age, sex, SEER stage, surgery, and chemotherapy were independent prognostic factors for patients. Both surgery and chemotherapy could significantly prolong the survival of patients, and there was no statistical difference between the prognosis of patients treated with chemotherapy alone and those treated with surgery alone.
肝血管肉瘤(HAS)较为罕见,是肝脏原发性血管源性恶性肿瘤。其临床特征、治疗策略管理及预后均不明确。
本研究为 SEER 数据库的回顾性研究。采用 Kaplan-Meier 法进行生存分析。采用单因素和多因素 Cox 模型确定危险因素。采用倾向评分匹配(PSM)分析消除混杂偏倚。构建列线图,并使用 C 指数测量其性能。
共纳入 1975 年至 2016 年间诊断的 300 例 HAS 患者,估计癌症特异性生存率(CSS)的中位数为 1 个月。手术组和化疗组的 CSS 中位数均为 6 个月。年龄(HR=1.5206,p=0.0058)、性别(HR=1.3906,p=0.0391)、SEER 分期(HR=1.4426,p<0.0001)、手术(HR=0.4493,p=0.0001)和化疗(HR=0.28161,p<0.0001)是潜在的独立预后因素。在这些 HAS 患者中,有 29 例接受了单纯手术治疗,63 例接受了单纯化疗。对仅手术组和仅化疗组进行 1:1 PSM 以选择候选者。生存分析显示,仅手术组的中位生存时间为 3 个月,仅化疗组的中位生存时间为 5 个月,两组之间无统计学差异。最后构建了一个列线图,C 指数为 0.754。
HAS 较为罕见,预后不良。研究发现,年龄、性别、SEER 分期、手术和化疗是患者的独立预后因素。手术和化疗均能显著延长患者的生存时间,单独化疗与单独手术治疗的患者预后无统计学差异。